Terms: = Pancreatic cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
63 results:
1. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C; Derangère V; Gaudillière-Le Dain G; Huppe T; Rageot D; Ilie A; Vienot A; Borg C; Monnien F; Bibeau F; Truntzer C; Ghiringhelli F;
Oncoimmunology; 2024; 13(1):2294563. PubMed ID: 38169969
[TBL] [Abstract] [Full Text] [Related]
2. Identification of foxp3
Gong R; Chen X; Sun X; Zhang Y; Wang J; Yu Q; Lei K; Ren H
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C294-C303. PubMed ID: 38047300
[TBL] [Abstract] [Full Text] [Related]
3. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
[TBL] [Abstract] [Full Text] [Related]
6. pH-Responsive Zinc Ion Regulating Immunomodulatory Nanoparticles for Effective cancer Immunotherapy.
Lim B; Kim KS; Na K
Biomacromolecules; 2023 Sep; 24(9):4263-4273. PubMed ID: 37616157
[TBL] [Abstract] [Full Text] [Related]
7. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
9. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer.
Tanaka R; Eguchi S; Kimura K; Ohira G; Tanaka S; Amano R; Tanaka H; Yashiro M; Ohira M; Kubo S
PLoS One; 2023; 18(1):e0280348. PubMed ID: 36693070
[TBL] [Abstract] [Full Text] [Related]
11. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers.
Kim JE; Kim H; Kim B; Chung HG; Chung HH; Kim KM; Kim SH; Jeong WK; Kim YK; Min JH; Heo JS; Han IW; Shin SH; Park HC; Yu JI; Park JO; Kim ST; Hong JY; Lee SH; Lee KH; Lee JK; Lee KT; Jang KT; Park JK
Cancer Med; 2023 Apr; 12(7):7748-7761. PubMed ID: 36650632
[TBL] [Abstract] [Full Text] [Related]
13. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by IL-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract] [Full Text] [Related]
14. Ultrasound improved immune adjuvant delivery to induce DC maturation and T cell activation.
Wang X; Shi Z; Luo J; Zeng Y; He L; Chen L; Yao J; Zhang T; Huang P
J Control Release; 2022 Sep; 349():18-31. PubMed ID: 35780954
[TBL] [Abstract] [Full Text] [Related]
15. Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells.
Leung SS; Borg DJ; McCarthy DA; Boursalian TE; Cracraft J; Zhuang A; Fotheringham AK; Flemming N; Watkins T; Miles JJ; Groop PH; Scheijen JL; Schalkwijk CG; Steptoe RJ; Radford KJ; Knip M; Forbes JM
Diabetes; 2022 Sep; 71(9):1994-2008. PubMed ID: 35713929
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic value of tumor-infiltrating CD163
Kinoshita J; Fushida S; Yamaguchi T; Moriyama H; Saito H; Shimada M; Terai S; Okamoto K; Nakamura K; Ninomiya I; Yagi S; Inaki N
BMC Cancer; 2022 Jun; 22(1):608. PubMed ID: 35658848
[TBL] [Abstract] [Full Text] [Related]
17. The Effects of treatment on Peripheral Blood Immune Cell Profile in pancreatic Ductal Adenocarcinoma (PDAC).
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Zvirblis T; Sileikis A
Anticancer Res; 2022 Jun; 42(6):3067-3073. PubMed ID: 35641268
[TBL] [Abstract] [Full Text] [Related]
18. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Hyung J; Lee H; Jin H; Lee S; Lee HJ; Gong G; Song TJ; Lee SS; Hwang DW; Kim SC; Jeong JH; Ryoo BY; Kim K; Yoo C
ESMO Open; 2022 Jun; 7(3):100484. PubMed ID: 35576696
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
[TBL] [Abstract] [Full Text] [Related]
20. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
[TBL] [Abstract] [Full Text] [Related]
[Next]
